Your browser doesn't support javascript.
loading
Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice.
Okamoto, Masahiro; Tajiri, Wakako; Ueo, Hiroki; Masuda, Takanobu; Ijichi, Hideki; Koga, Chinami; Nakamura, Yoshiaki; Taguchi, Kenichi; Ohno, Shinji; Tokunaga, Eriko.
Affiliation
  • Okamoto M; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Tajiri W; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Ueo H; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Masuda T; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Ijichi H; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Koga C; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Nakamura Y; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Taguchi K; Department of Pathology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Ohno S; Breast Cancer Center, Cancer Institute Hospital, Tokyo, Japan.
  • Tokunaga E; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan eriko.tokunaga.pw@mail.hosp.go.jp.
Anticancer Res ; 40(6): 3315-3323, 2020 Jun.
Article in En | MEDLINE | ID: mdl-32487627
ABSTRACT
BACKGROUND/

AIM:

To evaluate the improvement in the prognosis by adjuvant trastuzumab in clinical practice and the risk factors for distant recurrence, we retrospectively investigated the prognosis of HER2-positive early breast cancer in our department before and after the introduction of adjuvant trastuzumab. PATIENTS AND

METHODS:

Cohorts A and B included 161 and 182 cases, respectively, who underwent surgery before (2000-2007) and after (2008-2015) the introduction of adjuvant trastuzumab.

RESULTS:

The rates of relapse-free and distant metastasis-free survival were significantly better in cohort B than in cohort A. The risk factors of distant recurrence found in cohort A, such as the presence of lymph node metastasis, lymphatic invasion, and a low histological grade, did not increase the risk in cohort B.

CONCLUSION:

Many risk factors seemed to have been negated by adjuvant trastuzumab administration. Therefore, further escalation of adjuvant treatment should be carefully considered.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Anticancer Res Year: 2020 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Anticancer Res Year: 2020 Type: Article Affiliation country: Japan